Cellworks > Resources > Bibliography

Bibliography

V2a Kit - From Vasculogenesis to Angiogenesis

2014

BPC 157 and blood vessels.
Authors

Seiwerth, Sven, et al.

Journal

Current Pharmaceutical Design 20.7 (2014): 1121-1125.

Effects of BPC 157 on blood vessels after various types of damage and the different aspects of vascular response. BPC was found to be a potent angiomodulatory agent acting through different vasoactive pathways and systems. The V2a Kit: Vasculogenesis to Angiogenesis was used to investigate the angiogenic effect of BPC 157 both with and without VEGF and Suramin.

In vivo and in vitro properties of STX2484: a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer.
Authors

Stengel, C., et al.

Journal

British Journal Of Cancer 111.2 (2014): 300-308.

STZ2484 is a novel non-steroidal compound with potent anti-proliferative activity. V2a Kit: Vasculogenesis to Angiogenesis was used to investigate the effect of STX2484 on in vitro vessel formation.

Shed syndecan-2 inhibits angiogenesis.
Authors

De Rossi, Giulia, et al.

Journal

Journal Of Cell Science 127.21 (2014): 4788-4799.

Results demonstrate that shed syndecan-2 regulates angiogenesis by inhibiting endothelial cell migration in human and rat models; and reduces tumour growth. The V2a Kit: Vasculogenesis to Angiogenesis was used to investigate the effect of S2ED in vitro.

Soluble VEGF receptor-1 improves therapeutic efficacy of suicide gene therapy in an angiogenesis independent manner.
Authors

Samaranayake, Haritha D., et al.

Journal

Human Gene Therapy Ja (2014).

Demonstration of the feasibility of combining adenovirus-mediated soluble vascular endothelial growth factor-1 anti-angiogenic gene therapy with AdHSv-tk/GVC suicide gene therapy to treat experimental malignant gliomas. The functionality of Ads VEGFR-1 was tested using the V2a Kit: Vasculogenesis to Angiogenesis.

2013

Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells.
Authors

O'Brien, Keith, et al.

Journal

European Journal Of Cancer 49.8 (2013)

V2a Kit: Vasculogenesis to Angiogenesis used to study the effect of exosomes on vasculogenesis and angiogenesis

The impact of the receptor binding profiles of the vascular endothelial growth factors on their angiogenic features.
Authors

Nieminen, Tiina, et al.

Journal

Biochimica Et Biophysica Acta (BBA)-General Subjects 1840.1 (2014)

V2a Kit: Vasculogenesis to Angiogenesis used to determine the biological activity of VEGF

The novel alkylating prodrug melflufen (J1) inhibits angiogenesis
Authors

Strese, Sara, et al.

Journal

Biochemical Pharmacology86.7 (2013): 888-895.

Melflufin can be activated by Aminopeptidase N (APN). APN has been reported to have a functional role in tumour angiogenesis and reported to be over-expressed in human tumours. The V2a Kit: Vasculogenesis to Angiogenesis was used to illustrate the superior anti-angiogenic effect of melflufen compared to melphalan.

Call for papers

Cellworks would like to hear from all customers who have published using Cellworks products.

Please contact Caltag Medsystems office@caltagmedsystems.co.uk or telephone +44 (0)1280 827460 with the following details:

  • Researcher Name
  • Researcher Email
  • Article and Journal Title
  • Cellworks Product Used

Webmaster: AnnWebCom  |  Cellworks is a Caltag Medsystems company.  |  © 2012-2019 Caltag Medsystems Ltd. - all rights reserved  |  Privacy & Cookies